Olfr574 Inhibitors
Olfr574, a member of the olfactory receptor family, plays a crucial role in olfaction by detecting specific odorants and initiating signaling cascades. This receptor is involved in intricate cellular processes, mediating responses to various olfactory stimuli. The function of Olfr574 is tightly regulated, and its precise modulation is essential for proper olfactory signaling. Inhibition of Olfr574 can be achieved through direct or indirect means. Direct inhibitors specifically target the receptor itself, while indirect inhibitors focus on influencing the signaling pathways associated with Olfr574. The presented chemicals act as indirect inhibitors by targeting key cellular pathways, leading to altered Olfr574 expression.
Imatinib, for instance, indirectly inhibits Olfr574 by targeting c-Abl kinase, disrupting the downstream MAPK pathway and subsequently affecting Olfr574 expression. Similarly, Sorafenib acts as a multikinase inhibitor, impacting the Ras/Raf/MEK/ERK pathway, leading to indirect downregulation of Olfr574. SB-431542 functions as a TGF-β receptor inhibitor, attenuating downstream Smad signaling and indirectly inhibiting Olfr574. Other inhibitors, such as LY294002, U0126, SP600125, Wortmannin, PD98059, Rapamycin, AZD5363, LY2090314, and BAY 11-7082, target specific cellular pathways like PI3K/Akt, MAPK, JNK, mTOR, GSK-3, and NF-κB, respectively. These compounds induce indirect inhibition by interfering with the associated molecular cascades, ultimately impacting Olfr574 expression. In summary, Olfr574 is a pivotal player in olfactory signaling, and its inhibition can be achieved through indirect modulation of key cellular pathways. The presented chemicals provide a strategic approach to influence Olfr574 expression indirectly, offering valuable insights into potential avenues for further research on olfactory receptor regulation and cellular responses.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits Olfr574 indirectly by targeting the c-Abl kinase. This disrupts the downstream MAPK pathway, affecting Olfr574 expression. The inhibition occurs through altered signaling cascades in response to c-Abl modulation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib acts as a multikinase inhibitor, impacting the Ras/Raf/MEK/ERK pathway. By disrupting this pathway, Olfr574 expression is indirectly downregulated. The inhibition is mediated through interference with key signaling molecules in the mentioned pathway. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 functions as a TGF-β receptor inhibitor, attenuating downstream Smad signaling. This indirectly inhibits Olfr574 by interfering with the TGF-β pathway, leading to altered cellular responses and reduced expression of the target gene. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly influences Olfr574 by modulating the PI3K/Akt/mTOR pathway. This inhibition results in altered intracellular signaling, affecting Olfr574 expression through disruptions in the associated molecular cascades. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126, a MEK inhibitor, hinders the MAPK pathway, impacting Olfr574 indirectly. By disrupting the MEK-ERK signaling axis, U0126 leads to altered gene expression patterns, serving as an indirect inhibitor of Olfr574 through interference with its downstream pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, indirectly inhibits Olfr574 by targeting the JNK signaling pathway. This disruption alters the cellular responses linked to Olfr574 expression, making SP600125 an indirect inhibitor through interference with the JNK-related cascades. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, indirectly regulates Olfr574 by disrupting the PI3K/Akt pathway. This leads to modified intracellular signaling, impacting Olfr574 expression through interference with the associated molecular cascades and downstream effectors. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, indirectly inhibits Olfr574 by disrupting the MAPK pathway. Through the inhibition of MEK, PD98059 alters the ERK signaling cascade, resulting in indirect downregulation of Olfr574 expression by interfering with its associated molecular pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly influences Olfr574 by modulating the mTOR signaling pathway. This indirect inhibition leads to altered cellular responses, affecting Olfr574 expression through disruptions in the associated molecular cascades and downstream targets. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363, an Akt inhibitor, indirectly inhibits Olfr574 by targeting the PI3K/Akt/mTOR pathway. This inhibition results in altered intracellular signaling, impacting Olfr574 expression through disruptions in the associated molecular cascades and downstream effectors. | ||||||